IDT Relocates Bay Area Operations to Expanded Sunnyvale Innovation Hub

Genomics leader relocates to an expanded footprint in Sunnyvale New location enables customer continuity and provides increased innovation space to driv...

January 15, 2026 | Thursday | News
Hongene Biotech Secures Gates Foundation Grant to Advance Equitable mRNA Vaccine Manufacturing

Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use ...

January 14, 2026 | Wednesday | News
Oxford Nanopore’s GridION™ Dx Receives CE and UKCA Marking in UK and Europe

Oxford Nanopore has reached a major regulatory milestone with the registration of its first In Vitro Diagnostic (“IVD”) device in the UK an...

January 13, 2026 | Tuesday | Regulatory
Tensive Reports Positive Pivotal Trial Results for REGENERA™ in Lumpectomy Patients

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endp...

January 09, 2026 | Friday | News
Prokaryotics and Basilea Enter Collaboration to Develop First-in-Class Broad-Spectrum Antifungal

Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives,  announced an agree...

January 08, 2026 | Thursday | News
Nucleome Therapeutics Nominates First-in-Class Monoclonal Antibody Programme Targeting Inflammation Resolution

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases...

January 08, 2026 | Thursday | News
Diamyd Medical Aligns with FDA to Accelerate Phase 3 DIAGNODE-3 Efficacy Readout in Type 1 Diabetes

Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, ...

December 30, 2025 | Tuesday | News
FDA Approves Omeros’ YARTEMLEA® as the First and Only Treatment for Transplant-Associated Thrombotic Microangiopathy

First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangio...

December 26, 2025 | Friday | News
datma and Rhythm Biosciences Launch Exploratory Collaboration to Advance Genomic-Integrated Cancer Risk Prediction

The two companies will explore how datma's federated ecosystem can support Rhythm Biosciences' diagnostic development efforts as they shape a future comm...

December 25, 2025 | Thursday | News
Wasatch BioLabs and Agilent Partner to Expand Access to Native-Read Targeted Methylation Sequencing

Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, announced a co-marketing agreement with Agilent Technologies to ...

December 23, 2025 | Tuesday | News
FNIH Secures FDA Qualification of Hip Bone Mineral Density as Surrogate Endpoint in Osteoporosis Trials

Measuring change in bone mineral density, rather than fracture occurrence, promises to speed development of new drugs to treat osteoporosis. FNIH Bi...

December 22, 2025 | Monday | News
GE HealthCare to Deploy 300+ Advanced CT Scanners Across Indonesia Under Landmark SIHREN Program

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicab...

December 18, 2025 | Thursday | News
Neupulse Launches Drug-Free Wearable Offering New Hope for People Living With Tourette Syndrome

Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...

December 17, 2025 | Wednesday | News
Vanda Targets Mid-2026 Approval With Imsidolimab BLA for Generalized Pustular Psoriasis

Vanda Pharmaceuticals Inc.  announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ims...

December 16, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close